PolyActiva successfully completes initial clinical trial
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
x
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
PolyActiva completes recruitment in key Phase I
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
PolyActiva commences its first Phase
PolyActiva commences its first Phase I clinical trial.
PolyActiva raises AUD$9.2M
PolyActiva raises AUD$9.2M in Series B venture funding.